Obalon Therapeutics, Inc. (OBLN): Price and Financial Metrics

Obalon Therapeutics, Inc. (OBLN)

Today's Latest Price: $6.02 USD

0.83 (15.99%)

Updated Jan 22 4:00pm

Add OBLN to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 186 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

OBLN Stock Summary

  • OBLN has a market capitalization of $46,779,602 -- more than approximately only 10.07% of US stocks.
  • Revenue growth over the past 12 months for Obalon Therapeutics Inc comes in at -48.92%, a number that bests just 5.24% of the US stocks we're tracking.
  • The volatility of Obalon Therapeutics Inc's share price is greater than that of 97.39% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Obalon Therapeutics Inc are XXII, ICAD, LEAF, CTSO, and FLDM.
  • Visit OBLN's SEC page to see the company's official filings. To visit the company's web site, go to www.obalon.com.

OBLN Stock Price Chart Interactive Chart >

Price chart for OBLN

OBLN Price/Volume Stats

Current price $6.02 52-week high $10.77
Prev. close $5.19 52-week low $0.62
Day low $5.84 Volume 68,476,400
Day high $7.57 Avg. volume 38,826,352
50-day MA $1.65 Dividend yield N/A
200-day MA $1.06 Market Cap 46.78M

Obalon Therapeutics, Inc. (OBLN) Company Bio

Obalon Therapeutics, a commercial-stage medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It offers the Obalon balloon system designed to provide weight loss in obese patients. The company was founded in 2008 and is based in Carlsbad, California.

OBLN Latest News Stream

Event/Time News Detail
Loading, please wait...

OBLN Latest Social Stream

Loading social stream, please wait...

View Full OBLN Social Stream

Latest OBLN News From Around the Web

Below are the latest news stories about Obalon Therapeutics Inc that investors may wish to consider to help them evaluate OBLN as an investment opportunity.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Obalon Therapeutics, Inc.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Obalon Therapeutics, Inc. ("Obalon" or the "Company") (NASDAQ: OBLN) in connection with the proposed merger of the Company with ReShape Lifesciences Inc. ("ReShape") (OTCQB: RSLS). Under the terms of the merger agreement, ReShape will acquire Obalon in an all-stock transaction, pursuant to which Obalon will be renamed ReShape Lifesciences Inc. and will trade under the NASDAQ ticker symbol "RSLS." Upon completion of the merger, ReShape stockholders will own approximately 51% of the combined company's outstanding common stock and Obalon stockholders will own approximately 49%.

Yahoo | January 21, 2021

ROCE Insights For Obalon Therapeutics

Obalon Therapeutics (NASDAQ:OBLN) reported Q3 sales of $44.00 thousand. Earnings fell to a loss of $1.56 million, resulting in a 62.5% decrease from last quarter. Obalon Therapeutics collected $703.00 thousand in revenue during Q2, but reported earnings showed a $4.16 million loss.What Is ROCE? Changes in earnings and sales indicate shifts in Obalon Therapeutics's Return on Capital Employed, a measure of yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q3, Obalon Therapeutics posted an ROCE of -0.26%.It is important to keep in mind ROCE evaluates past performance and is not used as a predictive tool. It is a good measure of a company's recent per...

Yahoo | January 21, 2021

Obalon Therapeutics, Caladrius Biosciences leads healthcare gainers; BioLineRx, AcelRx Pharmaceuticals among major losers

Gainers: Obalon Therapeutics (OBLN) +181%, Caladrius Biosciences (CLBS) +137%, Titan Medical (TMDI) +36%, Tiziana Life Sciences (TLSA) +31%, Gritstone Oncology (GRTS) +12%.Losers: BioLineRx (BLRX) -24%, AcelRx Pharmaceuticals (ACRX) -17%, Bionano Genomics (BNGO) -16%, Jaguar Health (JAGX) -13%, Acer Therapeutics (ACER) -11%....

Seeking Alpha | January 20, 2021

Obalon is up 76% after announcing merger with ReShape Lifesciences

Obalon Therapeutics (OBLN) is up ~75.8% after announcing a merger agreement with ReShape Lifesciences in an all-stock deal whereby the existing ReShape stockholders will have a majority of the ownership of the combined company that will be renamed as ReShape Lifesciences Inc.Following the completion of the merger, ReShape Lifesciences will trade...

Seeking Alpha | January 20, 2021

Obalon Therapeutics stock soars to lead all gainers on massive volume after ReShape merger deal

Shares of Obalon Therapeutics Inc. blasted six-fold higher on massive volume in afternoon trading Wednesday, after the weight loss technologies company announced an agreement to merge with weight loss solutions company ReShape Lifesciences Inc. . Obalon's stock rose 503.4% toward the highest close since JUne 2019, while trading volume soared to 395.4 million shares, compared with the full-day average of about 626,000 shares. The stock was the biggest gainer and most active on major U.S. exchanges on Wednesday. ReShape shares, which currently trade over the counter, rose 155%. When the merger is completed, ReShape shareholders will own 51% of the combined entity, and the company will be renamed Reshape Lifesciences Inc. and will trade on the Nasdaq under the ticker symbol "RSLS." "We are...

Yahoo | January 20, 2021

Read More 'OBLN' Stories Here

OBLN Price Returns

1-mo N/A
3-mo 523.83%
6-mo 734.95%
1-year 220.21%
3-year -85.28%
5-year N/A
YTD 301.33%
2020 -21.05%
2019 -90.82%
2018 -68.68%
2017 -25.31%
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.7796 seconds.